---
title: "Evaluation of a Screening Strategy for Sarcopenia: a Monocentric Prospective Cohort Study (STRAS)"
nct_id: NCT04827758
overall_status: TERMINATED
phase: NA
sponsor: Groupe Hospitalier de la Region de Mulhouse et Sud Alsace
study_type: INTERVENTIONAL
primary_condition: Sarcopenia
countries: France
canonical_url: "https://parkinsonspathways.com/agent/trials/NCT04827758.md"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT04827758"
ct_last_update_post_date: 2022-10-28
last_seen_at: "2026-05-12T06:44:04.485Z"
source: ClinicalTrials.gov (mirrored, no enrichment)
---
# Evaluation of a Screening Strategy for Sarcopenia: a Monocentric Prospective Cohort Study (STRAS)

**Official Title:** Evaluation of a Screening Strategy for Sarcopenia: a Monocentric Prospective Cohort Study

**NCT ID:** [NCT04827758](https://clinicaltrials.gov/study/NCT04827758)

## Key Facts

- **Status:** TERMINATED
- **Why Stopped:** insufficient recruitment to meet the objectives in time
- **Phase:** NA
- **Study Type:** INTERVENTIONAL
- **Target Enrollment:** 15
- **Lead Sponsor:** Groupe Hospitalier de la Region de Mulhouse et Sud Alsace
- **Conditions:** Sarcopenia
- **Start Date:** 2021-04-22
- **Completion Date:** 2022-09-23
- **CT.gov Last Update:** 2022-10-28

## Brief Summary

The main objective of this study is to determine the prevalence of sarcopenia in patients hospitalized in the follow-up care and rehabilitation units of the geriatrics department of the Mulhouse French hospital.

## Detailed Description

Secondary objectives

1. To assess the performance of the SARC-F questionnaire to screen for sarcopenia ;
2. To describe the characteristics of sarcopenic patients hospitalized in each follow-up care and rehabilitation unit (i.e. day hospital, full hospitalization);
3. To identify predictive factors of sarcopenia;
4. To determine, in the subgroup of patients hospitalized in the conventional follow-up care and rehabilitation unit (i.e. full hospitalization), the evolution of sarcopenia between admission and discharge of the following variables :

   1. muscle strength,
   2. muscle mass,
   3. functional ability,
   4. dependency.

Conduct of research

After receiving the written consent of the study participant, all of the following tests and questionnaires will be performed :

* SARC-F questionnaire,
* measurement of muscle strengh by a grip test,
* measurement of muscle mass by impedancemetry (ASM/size2),
* 4-meter walking speed test,
* Timed-Up and Go (TUG) test,
* ADL (Activities of Daily Living) and IADL (Instrumental Activities of Daily Living) questionnaires.

For patients in day hospital care, the study will end upon completion of these tests.

For patients hospitalized in the conventional follow-up care and rehabilitation unit (i.e. full hospitalization), a follow-up visit will be scheduled within 72 hours prior to the patient's discharge from the service, or at 3 months of hospitalization. The following tests and questionnaires will be performed during this visit:

* measurement of muscle strengh by a grip test,
* measurement of muscle mass by impedancemetry,
* 4-meter walking speed test,
* Timed Up and Go (TUG) test,
* ADL and IADL questionnaires.

## Eligibility

- **Minimum age:** 60 Years
- **Sex:** ALL
- **Healthy Volunteers:** No

```
Inclusion Criteria:

* Patient 60 years of age or older
* Patients hospitalized in the follow-up care and rehabilitation units (i.e. day hospital, full hospitalization) of the geriatrics department of the Mulhouse French hospital
* Patient who gave consent to participate in the study
* Affiliated or beneficiary of a social security scheme

Exclusion Criteria:

* Patient admitted for palliative care
* Bedridden patient
* Patient with major neurocognitive disorders preventing impedancemetry or grip test from being performed, or any other medical condition preventing impedancemtery or grip test from being performed
* Patient under legal protection
* Patient with an unstable psychiatric disorder
* Patient under guardianship or curatorship
* Patient already included in the study during a previous hospitalization

Secondary exclusion criteria :

\- For patients hospitalized in the conventional follow-up care and rehabilitation unit (i.e. full hospitalization), impedancemtry or grip test not performed within 7 days of admission.

Patients excluded secondarily will not be replaced.
```

## Arms

- **Patients hospitalized in the follow-up care and rehabilitation units** (OTHER)

## Interventions

- **Screening and diagnostic tests for sarcopenia** (PROCEDURE) — All of the following tests and questionnaires will be performed :

* SARC-F questionnaire,
* measurement of muscle strengh by a grip test,
* measurement of muscle mass by impedancemetry (ASM/size2),
* 4-meter walking speed test,
* Timed-Up and Go (TUG) test,
* ADL (Activities of Daily Living) and IADL (Instrumental Activities of Daily Living) questionnaires.

## Primary Outcomes

- **Number of patients with sarcopenia** _(time frame: Enrollment)_ — The diagnosis of sarcopenia will be established according to the 2018 criteria of the European Working Group On Sarcopenia in Older People (EWGSOP2) based on the evaluation of muscle strength and muscle mass. Sarcopenia will be defined by an abnormal value measured by a grip test and confirmed by an abnormal value of the ASM/size2 ratio measured by impedancemetry.

## Secondary Outcomes

- **Sensitivity, specificity, positive and negative predictive value of the SARC-F questionnaire** _(time frame: Enrollment)_
- **Characteristics of sarcopenic patients hospitalized in each follow-up care and rehabilitation unit (i.e. day hospital, full hospitalization)** _(time frame: Enrollment)_
- **Muscle strength** _(time frame: Hospital discharge assessed up to 3 months)_
- **Muscle mass** _(time frame: Hospital discharge assessed up to 3 months)_
- **4-meter walking speed test** _(time frame: Hospital discharge assessed up to 3 months)_
- **Timed-Up and Go test (TUG)** _(time frame: Hospital discharge assessed up to 3 months)_
- **ADL (Activities of Daily Living) questionnaire** _(time frame: Hospital discharge assessed up to 3 months)_
- **IADL (Instrumental Activities of Daily Living) questionnaire** _(time frame: Hospital discharge assessed up to 3 months)_

## Locations (1)

- GHRMSA - Hôpital Emile MULLER, Mulhouse, France

## Recent Field Changes (last 30 days)

- `sponsor.lead` — added _(2026-05-12)_
- `results.hasResults` — added _(2026-05-12)_
- `locations.ghrmsa - hôpital emile muller|mulhouse||france` — added _(2026-05-12)_
- `status.overallStatus` — added _(2026-05-12)_
- `status.whyStopped` — added _(2026-05-12)_
- `status.primaryCompletionDate` — added _(2026-05-12)_
- `status.completionDate` — added _(2026-05-12)_
- `status.lastUpdatePostDate` — added _(2026-05-12)_
- `design.phases` — added _(2026-05-12)_
- `design.enrollmentCount` — added _(2026-05-12)_
- `eligibility.criteria` — added _(2026-05-12)_
- `eligibility.minAge` — added _(2026-05-12)_
- `eligibility.sex` — added _(2026-05-12)_
- `outcomes.primary` — added _(2026-05-12)_
- `outcomes.secondary` — added _(2026-05-12)_
- `armsInterventions.arms` — added _(2026-05-12)_
- `armsInterventions.interventions` — added _(2026-05-12)_

---

*Canonical: https://parkinsonspathways.com/agent/trials/NCT04827758.md*  
*Source data (authoritative): https://clinicaltrials.gov/study/NCT04827758*  
*This page is a raw mirror with no AI summary, no editorial enrichment, and no Parkinson's-specific filtering.*